The Latest Cardiac and Vascular News
YOKNEAM, Israel, Jan. 13, 2025 /PRNewswire/ — ElastiMed Ltd. a leading innovator in wearable medical devices for treating and managing lymphatic and venous diseases, is proud to announce the appointment of Dr. Steve Elias as a member of its Medical Advisory Board, effective immediately….
NEW YORK, Jan. 13, 2025 /PRNewswire/ — WindRose Health Investors, LLC (“WindRose”), the New York-based healthcare private equity firm, announced that it has completed a strategic investment in CIVIE (“CIVIE” or the “Company”), an AI-powered ecosystem of radiology solutions. The Company’s…
ENGLEWOOD CLIFFS, N.J., Jan. 13, 2025 /PRNewswire/ — BRAIN.Q, is excited to announce the CE Mark for its BQ 2.0 system, designed to reduce disability following ischemic stroke, the number one cause of disability worldwide. Reducing stroke disability is often achieved through endovascular…
MOUNTAIN VIEW, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) — R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating peripheral arterial disease (PAD), is pleased to announce that it received WCG Institutional Review Board (IRB) approval for the ELITE-BTK Pivotal Trial of its MAGNITUDE Drug Eluting Next Generation Bioresorbable Scaffold for Below-the-Knee Peripheral Arterial Disease (PAD). This approval allows the trial to take place at institutions that utilize WCG IRB as their central IRB in the United States. Additionally, the company announced that the Centers for Medicare & Medicaid Services (CMS) has granted Category B approval for the investigational device exemption (IDE) study, ensuring Medicare coverage for the device, related and routine items, and services for the ELITE-BTK trial.
SAN FRANCISCO, Jan. 13, 2025 /PRNewswire/ — Piccolo Medical®, an emerging leader in catheter navigation devices for vascular access procedures, is proud to announce an exclusive distribution agreement with Spectrum Vascular™, a leading provider of vascular access and medication…
MIAMI–(BUSINESS WIRE)–Jan. 10, 2025– Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced the appointment of Paul A. LaViolette, current Co-Chairman of the Board, as Chief Executive Officer. “We are thrilled to have Paul assume […]
WASHINGTON, Jan. 10, 2025 /PRNewswire/ — The Heart Failure Society of America, in partnership with Elsevier, is proud to announce the appointment of Jason N. Katz MD, MHS (NYU Grossman School of Medicine, New York, NY) as the inaugural Editor-in-Chief of Journal of Cardiac…
DENVER–(BUSINESS WIRE)–TriSalus Life Sciences®, Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), TriSalus Life Sciences seeks to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies and our investigational immunotherapy, announced today the publication of research titled, “Pressure Enabled Drug Delivery (PEDD) Significantly Increases Intraarterial Delivery […]
MINNEAPOLIS & WASHINGTON–(BUSINESS WIRE)–Vensana Capital today announced the closing of Vensana Capital III with $425 million in committed capital. The fund was oversubscribed at its hard cap with the support of the firm’s existing limited partners alongside select new institutional investors, and it brings Vensana’s total capital under management to […]
BEDFORD, Mass.–(BUSINESS WIRE)–SpectraWAVE, Inc., a medical imaging company focused on improving the treatment and outcomes for patients with coronary artery disease (CAD), today announced the addition of two seasoned executives to its leadership team. Brad Davis has been named Chief Commercial Officer (CCO), and Bill Kelly has been named Chief […]
